Particle’s platform effectively triages patients for GLP-1 treatment using clinical data

‍In collaboration with LifeMD, Particle compliantly utilized clinical data to effectively and efficiently triage patients eligible for GLP-1 treatment. By assessing data from 200 patients provided by LifeMD, the study sought to identify patients who met criteria for GLP-1 treatment, had known contraindications to GLP-1 therapy, or were already being treated.

‍

Key areas of focus:

• Treatment eligibility
• Weight management
• Accelerated patient triage
  ‍

Background:

GLP-1 (Glucagon-like peptide-1) drugs are a class of medications primarily used to treat type 2 diabetes mellitus. These drugs mimic the action of GLP-1, a naturally occurring hormone that stimulates insulin release, suppresses glucagon secretion, slows gastric emptying, and reduces appetite. By enhancing glucose control and promoting weight loss, GLP-1 drugs have gained significance in managing diabetes and obesity-related conditions.

‍

Methodology:

Data from 200 patients was examined with the intention of identifying those who would be suitable candidates for weight loss treatment with a GLP-1 agonist.

Particle’s platform leveraged clinical code sets to find relevant medical records using BMI, height, and weight, as well as diagnosis codes for diabetes, hypertension, coronary artery disease, hyperlipidemia, osteoarthritis, obstructive sleep apnea, medullary thyroid cancer, pancreatitis, and gallbladder disease.

Medication codes for GLP-1 agonists and insulin were also retrieved.

‍

Screening Criteria:

‍

‍

Results:

‍

‍

Conclusion:

Out of 200 patients, 61 individuals were ruled out as potential candidates for GLP-1 treatment based on screening criteria. This could potentially save LifeMD- affiliated physicians significant time that would otherwise be spent determining medication appropriateness. As a result, these patients could be rapidly redirected to other weight management resources. 

32 patients were determined to be a good fit for therapy and could be streamlined into appropriate medication consultation. The remaining 107 patients would continue with a clinician visit to determine appropriate therapy. 

Access to clinical data through Particle’s platform may enhance patient care by accelerating the triage and selection process for potential treatment, while enabling informed decision-making for healthcare providers.